| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nab-paclitaxel |
| Brand | Abraxane® |
| Indication | In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas. |
| Assessment Process | |
| Rapid review commissioned | 23/01/2014 |
| Rapid review completed | 02/03/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 23/05/2014 |
| NCPE assessment completed | 05/09/2014 |
| NCPE assessment outcome | Reimbursement not recommended |
The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).
The HSE has approved reimbursement following confidential price negotiations December 2015
